HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

American Biogenetic Sciences files fibrinogen test for clearance:

This article was originally published in Clinica

  • News

Executive Summary

American Biogenetic Sciences has filed a 510(k) application to the FDA for its functional intact fibrinogen test for the quantitative determination of fibrinogen in human plasma. American Biogenetic Sciences, based in Copiague, New York, has moved its R&D operations into BioSquare research and business park in Boston, Massachusetts. BioSquare was developed by Boston University and Boston Medical Center.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

The Aspirin Test For AI?

Beiersdorf Partners With Biopharma For Anti-Aging Skin Care Innovation; Beauty Business News

Clasado, Probi Funded Study Shows Synergistic Effect Of Synbiotic Combination

See All
UsernamePublicRestriction

Register

MT083869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By